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Abstract
Introduction: There is an increasing number of adrenal being tumours discovered incidentally during imaging examinations performed 
for many different indications. Radiological findings suggesting adrenal pathology may be caused by true adrenal tumours or by other 
retroperitoneal masses. Generally, the larger the tumour, the higher the possibility of adrenal cancer.
Material and methods: Analysis of our data — 139 operations performed over 11 years (2004–2014) in patients with tumours in the adrenal 
area larger than 5 cm.
Results: The most common finding was adrenal cancer (25.2%), benign adenoma (24.5%), pheochromocytoma (12.9%), and metastatic 
cancer (10.1%). In total, there were 19 various histopathological diagnoses in this group.
Conclusion: Although adrenal cancer is the most likely diagnosis in large adrenal tumours, a broad spectrum of various adrenal and 
retroperitoneal tumours with size more than 5 cm can be found in such patients. (Endokrynol Pol 2017; 68 (4): 411–415)
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Streszczenie
Wstęp: Obecnie obserwuje się zwiększoną liczbę guzów nadnerczy wykrywanych przypadkowo przy okazji badań obrazowych wykony-
wanych z różnych wskazań. Zmiany opisywane jako guzy nadnerczy mogą być zmianami samych nadnerczy, jak i innymi patologiami 
przestrzeni zaotrzewnowej. Wraz ze wzrostem wielkości guza rośnie ryzyko jego złośliwego charakteru. 
Materiał i metody: Przedstawiamy analizę 139 pacjentów z guzami nadnerczy większymi niż 5 cm, operowanymi w ciągu 11 lat w latach 
2004–2014. 
Wyniki: Najczęstszymi rozpoznaniami były: rak kory nadnercza (25,2%), gruczolak (24,5%), guz chromochłonny (12,9%), zmiany prze-
rzutowe (10,1%). Łącznie w tej grupie chorych postawiono 19 różnych rozpoznań histopatologicznych. 
Wniosek: Rak kory nadnercza jest najbardziej prawdopodobnym rozpoznaniem u chorych z dużymi guzami nadnerczy, jakkolwiek 
w tej grupie chorych można się spodziewać licznych, różnych, rzadszych patologii. (Endokrynol Pol 2017; 68 (4): 411–415)
Słowa kluczowe: guzy nadnerczy, duże zmiany nadnerczy, chirurgia nadnerczy
Introduction
The presence of adrenal mass is reported in 1–4% 
of patients undergoing imaging studies for various 
reasons [1] The prevalence of such findings increases 
with increasing age [2, 3]. The majority of these tu-
mours are benign non-functional lesions, but certain 
patient’s characteristic and large size are predictors of 
malignancy [4].
Among all adrenal tumours the most common is 
non-functioning benign lesion (82.5%), followed by 
cortisol secreting adenoma (5.3%), pheochromocytoma 
(5.1%), adrenocortical carcinoma (4.7%), metastatic le-
sion (2.5%), and aldosteronoma (1%) [5].
However, many retroperitoneal pathologies may be 
confused with adrenal tumours on preoperative imag-
ing examinations [6].
When tumour size is exceeds 6 cm, the possibility of 
malignancy increases [7–9]. All such patients are can-
didates for surgical treatment as the only one offering 
the chance for cure.
We would like to present our experience with 139 
operations performed in our institution in patients with 
tumours larger than 5 cm in the adrenal area during an 
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eleven-year period (2004–2014). Because our institution 
is part of the Institute of Oncology, the patients referred 
to us were preselected. All of them were presumed to 
have a higher risk of malignancy and/or had atypical 
appearance of the mass seen in cross-sectional imaging. 
Material and methods
Between 2004 and 2014 a total of 287 patients with vari-
ous adrenal tumours were referred to our centre from 
departments of endocrinology in the whole Poland. 
Initial diagnostic procedures (hormonal status, imag-
ing examinations) were performed mostly in referring 
centres. Indications for surgery were established based 
on the hormonal activity of the tumour and its appear-
ance in ultrasound, CT, MR, and sometimes PET-Ct 
scans. Based on NIH guidelines from 2004 [10], tumours 
larger 6 cm were referred to surgery independently of 
their other radiological and hormonal features. Tumours 
smaller than 6 cm were treated with surgery if they 
were heterogeneous, had irregular or unclear margins, 
high density and delayed washout, areas of necrosis, 
haemorrhage or calcifications, and an increase in size 
exceeding 1 cm on consecutive CT scans. 
In this group a total of 139 patients with tumours 
larger than 5 cm were identified. There were 85 women 
and 54 men. The female/male ratio was 1.57, and the age 
range was 23–85 years. Mean age at the time of operation 
was 54.9 years (SD 13.6), and it was slightly higher for men 
56.6 years (SD 14.5) than for women 53.8 years (SD 13.2).
Based on preoperative investigations, presumptive 
diagnoses were: adrenal carcinoma — 41 patients (F-
33, M-8), pheochromocytoma — 18 patients (F-9, M-9), 
myelolipoma seven patients (F-2, M-5), and metastatic 
cancer — 15 patients (F-5, M-10). Most of these patients 
were the ones with “non-adenoma” lesions 58 (F-40, 
M-18). In these cases, presumptive diagnosis was not 
established, but their phenotype was estimated as not 
typical for adenoma.
Various hormonal disturbances were present in 
79 patients (56.8%). Subclinical hypercortisolaemia 
was a more frequent disorder, found in 41 subjects 
(29.5%). In 23 patients (16.5%) pheochromocytoma 
was suspected due to increased urinary catecholamine 
secretion; however, histological examination confirmed 
this diagnosis only in 18 tumours. In six cases primary 
hyperaldosteronism, and in nine cases hyperandrogen-
ism were diagnosed. 
Twenty-four out of 139 patients had previously 
diagnosed and treated cancer in another localisation: 
colon and rectum — six patients, lung — seven, breast 
— three, kidney — three, uterus — one, bladder — one, 
prostate — one, anal cancer — one, and shwannoma 
(mediastinum) — one. 
All patients were operated under general anaes-
thesia with appropriate antibiotic prophylaxis using 
the second generation of cephalosporin (cefuroxime) 
according to hospital standards. All patients received 
perioperatively low-molecular-weight heparins as ve-
nous thromboembolism prophylaxis. Cross-matched 
blood was reserved for patients with large tumours or 
essential comorbidities. The typical surgical approach 
was transabdominal lateral flank. Laparoscopic tech-
nique is applied in our institution, but had not been 
used in patients with tumours measuring more than 
5 cm and with suspected cancer. 
Seventy left adrenalectomies, 59 right, and 10 bilat-
eral adrenalectomies (at least one of the tumours was 
larger than 50 mm), as well as two resections of other 
retroperitoneal tumours, were performed. The decision 
to perform of bilateral adrenalectomy was always made 
together with the referring endocrinological centre. 
Results
The size of the tumour measured on histopathological 
examination ranged from 50 to 250 mm. Results of this 
findings are displayed in Table I. The five most common 
adrenal lesions, including cancer, adenoma, pheochro-
mocytoma, metastatic cancer, and myelolipoma, were 
responsible for 78.4% of adrenal tumours in this series. 
Thirty-eight of 139 patients (27.3%) had very large 
tumours (not smaller than 10 cm) removed. Among 
this group of patients, the most common diagnosis was 
adrenocortical cancer — 24 (63.2 %) and metastases — 
5 (13.2 %). The mean age of patients with metastases 
was higher than of those with the cancer. Characteristics 
of this group are presented in Table II. 
In the whole series of 139 operations, we performed 
10 bilateral adrenalectomies. In such patients at least 
one of the tumours measured more than 5 cm. Charac-
teristic of patients with bilateral tumours are presented 
in Table III.
Discussion
Adrenal tumours represent a wide spectrum of pa-
thologies, ranging from benign non-functioning cortical 
adenoma to adrenocortical carcinoma. In an increasing 
number of patients, the adrenal tumours are discovered 
incidentally during abdominal imaging performed for 
other clinical indications. The indications for adrena-
lectomy are hormone excess or increased risk of malig-
nancy. The risk of malignancy in adrenal tumour is de-
termined by several factors including tumour size and 
radiographic features, such as irregular margins, high 
density, slow washout of contrast medium presence 
of necrosis, area of haemorrhage, and calcifications. 
413
Endokrynologia Polska 2017; 68 (4)
PR
A
C
E 
O
RY
G
IN
A
LN
E
Regardless of all these features, presumptive diagnosis 
is often delusive because of numerous different patholo-
gies which may exist in the adrenal area.
The 2002 National Institutes of Health consensus 
statement on incidentaloma recommended adrenal-
ectomy for all non-functioning tumours greater than 
6 cm in size. For tumours 4 to 6 cm, is recommended to 
take into account such factors as the tumour’s features 
on imaging studies, age, and general condition of the 
patient [10]. Some authors, however, suggest lowering 
absolute cut-off to 4 cm because most adrenocortical 
carcinomas (ACC) are > 4 cm in size [11]. In recently 
Table I. Histopathological diagnosis — tumours larger than 50 mm
Tabela I. Rozpoznania histopatologiczne — guzy powyżej 50 mm
Diagnosis Number  
[%]
Sex Age [years] Age [years] 
mean / SD
Tumour size 
[mm]
Tumour size 
[mm] mean/SD
Cancer 35 (25.2) 28K, 7M 23–73 49.5/13.6 50–250 122.5 /45.5
Adenoma 34 (24.5) 25K, 9M 27–78 55.1/12.0 50–85 62.9/10.2
Pheochromocytoma 18 (12.9) 8K, 10M 30–77 55.8/12.6 55–135 75.4/19.3
Metastases 14 (10.1) 3K, 11M 58–79 66.3/6.6 51–130 88.6/25.1
Myelolipoma 8 (5.75) 3K, 5M 30–78 59.8/17.3 60–110 83.75/17.7
Ganglioneuroma 4 (2.8) 2K, 2M 39–74 53.3/14.7 50–85 67.5/15.6
Cysts 4 (2.8) 3K, 1M 43–68 51.5/11.3 50–95 66.3/19.7
Cortical hyperplasia 4 (2.8) 3K, 1M 31–62 49.8/13.2 50–110 81/26.8
Pseudocysts 3 (2.15) 2K, 1M 33–56 47/12.3 60–100 80/20
Haemorrhage with post-haemorrhage 
changes
3 (2.15) 1K, 2M 49–76 65.3/14.4 55–90 71.7/17.6
Shwannoma 2 (1.4) 1K, 1M 25–46 35.5 /14.8 60–110 85/35.4
Paraganglioma 2 (1.4) 1K, 1M 64–60 57/4.2 60–65 62.5/3.5
Hemangioma 2 (1.4) 2K 64–67 65.5/2.1 50–85 67.5/34.7
Haemangiolipoma 1 (0.7) M 63 65
Both adrenocortical carcinoma and 
malignant pheochromocytoma
1 (0.7) K 25 170
Leiomyosarcoma 1 (0.7) M 85 120
primary myelofibrosis 1 (0.7) K 40 70
Neurogenic sarcoma 1 (0.7) M 65 125
Lipoma 1 (0.7) K 70 90
Table II. Histopathological diagnosis — tumours larger than 100 mm
Tabela II. Rozpoznania histopatologiczne — guzy powyżej 100 mm
Diagnosis Number [%] Sex Age [years] Age [years] 
mean/SD
Tumour size 
[mm]
Tumour size [mm] 
mean/SD
Cancer 24 (63.15) 18K, 6M 23–73 50.5/14.6 100–250 144.8/38.0
Metastases 5 (13.15) 1K, 4M 59–79 65.8/7.7 100–130 116/13.4
Myelolipoma 2 (5.3) 2M 56–74 65/12.7 100–110 105/7.1
Pheochromocytoma 1 (2.6) K 55 135
Leiomyosarcoma 1 (2.6) M 85 120
Pseudocysts 1 (2.6) M 56 100
Neurogenic sarcoma 1 (2.6) M 65 125
Shwannoma 1 (2.6) M 25 110
Cortical hyperplasia 1 (2.6) M 53 110
Both adrenocortical carcinoma and 
malignant pheochromocytoma
1 (2.6) K 25 170
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published guidelines, authors voted against a certain 
cut-off in diameter of the tumour, and suggested that 
an individualised approach was most appropriate [12]. 
It is worth remembering that although attenuation 
value of < 10 Hounsfield units is the most widely used 
attenuation value for the diagnosis of lipid-rich benign 
adenomas, lipid poor adenomas with higher value 
represent 10–40% of all adenomas [13]. Even such tu-
mours as myelolipomas, although they are benign, are 
recommended to be surgically removed when they are 
bigger than 4 cm [14, 15]. According to current Polish 
recommendations, tumour size larger than 5 cm is one 
of the additional criteria for the surgical treatment of an 
incidentaloma [16], so we decided to analyse tumours 
of this size. Although adrenal cancer was the most 
common pathological finding in our series of patients, 
its incidence accounted for just above a quarter of all 
tumours (25.2%). This percentage is still much higher 
than previously published by our co-workers — 14% 
for primary and metastatic adrenal cancers [17]. This 
discrepancy is caused by preselection of the referred 
to oncological centre patients with “unclear” or “suspi-
cious” imaging phenotype of the tumours. 
The presented material shows also a large variety 
of pathologies preoperatively estimated as oncologi-
cally suspicious adrenal mass. Among 19 pathologic 
diagnoses, the five most common (cancer, adenoma, 
pheochromocytoma, metastatic cancer, and myeloli-
poma) accounted for 78.4% of cases. A wide spectrum 
of histological profiles of removed adrenal tumours was 
previously described [6]. Also, in our series we found 
some unexpected and rarely occurring lesions, for 
example Schwannoma (two cases), haemangiolipoma 
(one case), or leiomyosarcoma (one case). These rare 
cases constitute up to 21.6% of all operated tumours. 
Tumours like primary adrenal leiomyosarcoma are ex-
tremely rare, and only approximately 30 cases have been 
reported so far in the English language literature [18]. 
We present as many different pathological diagnoses 
as previously reported on a similar number of patients, 
but we report many more malignant lesions [19].
Concerning the tumour size, the highest mean size 
on histopathological examination was seen for adrenal 
cancers, followed by metastases and myelolipomas. For 
all these tumours the mean size was greater than 80 mm. 
The size of adenomas in this series reached 180 mm, but 
the median size of carcinomas was still almost twice as big. 
The percentage of adrenal carcinomas in the subgroup 
with tumours larger than 10 cm was over 60%. Since the 
probability of adrenal carcinoma is extremely high in large 
adrenal tumours, the diagnosis in such cases should be 
completed very quickly to shorten the time to surgery. 
A distinct diagnostic challenge is posed by bilateral 
masses, which constitute about 15% of incidentally dis-
covered adrenal tumours [20, 21]. In the literature, meta-
static or infiltrative tumours, changes with underlying 
congenital adrenal cortical hyperplasia, bilateral adrenal 
cortical adenomas, or ACTH-independent macronodu-
lar adrenal hyperplasia (AIMAH) have been described 
as the most likely diagnoses in such cases. Attention is 
also paid to the necessity for “oncological vigilance” af-
ter detection of bilateral lesions [22]. However, a higher 
frequency of malignant lesions in bilateral adrenal 
tumours was not found in a larger series of patients 
with adrenal incidentalomas, compared to unilateral 
ones [21]. Also in our material, despite exceptionally 
large dimensions of the tumours, the most frequent 
diagnoses were bilateral adrenal adenomas or AIMAH 
(6/10 cases). Some authors found a higher incidence of 
subclinical hypercortisolaemia among patients with 
benign bilateral adrenal tumours than in patients with 
unilateral lesions [23]. In the cases of large bilateral le-
sions operated in our clinic there were no subclinical 
hypercortisolaemia; we only found hyperaldosteronism 
in one case. Even in two cases of large bilateral metasta-
ses, there was no adrenal insufficiency in these patients. 
Adrenal insufficiency, a state which is often suspected 
in cases of metastases to both adrenal glands, is in fact 
a rare symptom in such patients [24]. 
Conclusion
In conclusion, we have stated that the incidence 
of malignant lesions among tumours larger than 5 cm 
is high. In our opinion, all patients with large adrenal 
tumours should be considered for surgical treatment, 
often as the only one offering a chance of cure.
Table III. Characteristic of patients and histopathological 
findings with bilateral adrenalectomies
Tabela III. Charakterystyka pacjentów i rozpoznania 
histopatologiczne w przypadkach obustronnych 
adrenalektomii
Sex and age Histopathology Size of the tumours
F-44 Bilateral pheochromocytoma 40 and 75 mm
M-67 Bilateral metastases of 
prostate cancer
65 and 95 mm
K-44 Bilateral adenomas 55 and 55 mm
K-31 Bilateral cortical hyperplasia 90 and 95 mm
M-63 Bilateral haemangiolipoma 43 and 65 mm
M-61 Bilateral adenomas 60 and 70 mm
M-62 Bilateral metastases of lung 
cancer 
35 and 130 mm
M-59 Bilateral adenomas 45 and 60 mm
M-53 Bilateral cortical hyperplasia 100 and 95 mm
K-62 Bilateral adenomas 60 and 10 mm
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